COLTENE (CLTN) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
31 Jul, 2026Executive summary
Net sales reached CHF 112.8m in H1 2026, down 4.4% year-over-year in CHF but up 0.8% in local currencies due to currency effects.
EBIT margin declined to 5.1% from 6.4%, reflecting FX impacts, higher energy costs, and lower gross margin, partially offset by cost reductions.
Net profit was CHF 4.1m, down 5% year-over-year, with a stable net profit margin of 3.6%.
Free cash flow improved to CHF 4.8m from CHF -0.3m, driven by optimized inventories and working capital.
Strategic focus on go-to-market execution, innovation, digital platforms, and new leadership in sales and marketing.
Financial highlights
Net sales decreased by 4.4% to CHF 112.8m; up 0.8% at constant FX rates.
EBIT dropped 23.6% to CHF 5.1m; EBIT margin at 5.1%.
Net profit slightly decreased to CHF 4.1m; net profit margin unchanged at 3.6%.
Effective tax rate fell to 20.7% from 24.1%, aided by a one-time tax refund.
Operating expenses decreased by 5.3% year-over-year.
Outlook and guidance
Sales growth expected modestly above market, with lower single-digit growth for FY 2026 in local currencies.
EBIT margin guidance for FY 2026 set at 9–10%; medium-term target remains 13–15%.
Expects demand recovery in H2 2026, with improved order momentum already visible in June.
Latest events from COLTENE
- Net profit rose 3.9% despite lower sales, with strong margins and a positive outlook.CLTN
H1 202424 Jul 2026 - Net profit rose to CHF 20.5m as sales and margins improved, led by North America.CLTN
H2 202424 Jul 2026 - Sales and profit declined sharply in H1 2025, but a stronger second half is anticipated.CLTN
H1 202524 Jul 2026 - Net profit fell 27% and EBIT margin dropped to 8.8%, with growth and margin recovery targeted for 2026.CLTN
H2 202513 Mar 2026 - Aims for 3–5% annual growth, 13–15% EBIT margin by 2027, and leadership in dental innovation.CLTN
CMD 2024 Presentation20 Feb 2026